Hematology Pipeline Update (February 2016, Volume 2, Issue 2.1)

February 2016 Special Edition

Volume 2, Issue 2.1

This supplement features updated information on late-breaking drug approvals for bleeding disorders, leukemia, and myeloma.

Table of Contents

Hematology Pipeline Update 2016

ASH/FDA Joint Symposium on Late-Breaking Drug Approvals: Looking into the Future of Myeloma Treatment

Monday, February 1st, 2016
At the 2015 ASH Annual Meeting, the U.S. Food and Drug Administration (FDA) sponsored a session reviewing drugs that received FDA approval in November...

How Should Clinicians Be Using Newly Approved Drugs in Practice?

Monday, February 1st, 2016
In 2015, the U.S. Food and Drug Administration (FDA) approved several new therapies for the treatment of hematologic disorders – ranging from the first...

Hematology Pipeline Update 2016

Panobinostat Plus Bortezomib and Dexamethasone Safe in Transplant-Eligible Myeloma Patients

Monday, February 1st, 2016
The selective histone deacetylase (HDAC) inhibitor panobinostat was safe and effective when used in combination with bortezomib and dexamethasone (RVD) in patients with newly...

ABL001 Shows Signs of Overcoming TKI Resistance in Heavily Pretreated Patients with CML

Monday, February 1st, 2016
The small molecule ABL001 exhibits rapid anti-tumor activity in heavily pretreated patients with chronic myeloid leukemia (CML), according to research presented by Oliver G....

New Antibody-Drug Conjugate Demonstrates Anti-Leukemic Activity in CD33-Positive AML

Monday, February 1st, 2016
CD33 is expressed on myeloblasts in approximately 90 percent of acute myeloid leukemia (AML) cases – regardless of patient age, prior therapies, or mutational...

Survival Rates with Clofarabine Inferior to Standard Therapy in Older Patients with AML

Monday, February 1st, 2016
Despite demonstrating clinical activity in older patients with newly diagnosed acute myeloid leukemia (AML) in phase II studies, single-agent clofarabine failed to produce similar...

Hematology Pipeline Update 2016

Combo of Ixazomib, Lenalidomide, Dexamethasone Leads to Longer PFS in Relapsed/Refractory Multiple Myeloma

Monday, February 1st, 2016
The triplet combination of the oral proteasome inhibitor (PI) ixazomib and the immunomodulatory drugs lenalidomide and dexamethasone resulted in longer progression-free survival (PFS) than...

Daratumumab Combination Produces Durable Responses in Patients with RRMM

Monday, February 1st, 2016
The anti-CD38 monoclonal antibody daratumumab produces durable responses when used in combination with lenalidomide and dexamethasone in patients with relapsed/refractory multiple myeloma (RRMM), according...

Hematology Pipeline Update 2016

Targeting Antithrombin: The Key to Achieving Hemostatic Balance in Hemophilia Patients?

Monday, February 1st, 2016
Targeting the endogenous anticoagulant antithrombin (AT) in patients with hemophilia restored hemostatic balance and prevented severe bleeding in people with severe forms of the...

SHARE